Alonso Torres AM, Arévalo Bernabé AG, Becerril Ríos N, Hellín Gil M, Martínez Sesmero JM, Meca Lallana V, Ramió Torrentà Ll, Rodríguez Antigüedad A, Gómez Maldonado L, Triana Junco, Gómez Barrera M, Espinoza Cámac N, Oyagüez I
Cost Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain”
Pharmacoecon Open. https://doi.org/10.1007/s41669-023-00394-2
Estrada V, Górgolas M, Peña JA, Tortajada E, Castro A, Presa M, Oyagüez I
Epidemiologic and economic analysis of rapid antiretroviral therapy initiation with bictegravir/emtricitabine/tenofovir alafenamide in Spain
PharmacoEconomics – Open
https://doi.org/10.1007/s41669-022-00322-w
de Andrés-Nogales F, Casado MÁ, Trillo JL, Ruiz-Moreno JM, Martínez-Sesmero JM, Peralta G, Poveda JL, Ortiz P, Ignacio E, Zarranz-Ventura J, Udaondo P, Mur C, Álvarez E, Cervera E, Martínez M, Llorente I, Zulueta J, Rodríguez-Maqueda M, García-Layana A, Martínez-Olmos J
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema: The MULTIDEX-EMD Study
Pharmacoecon Open. 2020;4(4):615-624
Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, de Andrés-Nogales F, Suarez J, Polanco C, Soto J
Cost-effectiveness analysis of apixaban versus edoxaban in atrial fibrillation patients for stroke prevention
Pharmacoecon Open. 2020;4(3):485-497
Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Simón S, Oyagüez I